Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

589 ARTÍCULOS , VIENDO DEL 136 AL 150

Comparative safety and efficacy of cognitive enhancers for Alzheimer's dementia: a systematic review with individual patient data network meta-analysis

Veroniki AA, Ashoor HM, Rios P, Seitidis G, Stewart L, Clarke M, Tudur-Smith C, Mavridis D, Hemmelgarn BR, Holroyd-Leduc J, Straus SE, Tricco AC.

BMJ Open. 2022 Apr 26;12(4):e053012. doi: 10.1136/bmjopen-2021-053012.

Blood pressure, antihypertensive drugs, and incident frailty: The Multidomain Alzheimer Preventive Trial (MAPT)

Rouch L, Rolland Y, Hanon O, Vidal JS, Cestac P, Sallerin B, Andrieu S, Vellas B, Barreto PS; MAPT/DSA Group.

Maturitas. 2022 Aug;162:8-14. doi: 10.1016/j.maturitas.2022.03.001. Epub 2022 Mar 15.

Combination Therapy in Alzheimer's Disease: Is It Time?

Salehipour A, Bagheri M, Sabahi M, Dolatshahi M, Boche D.

J Alzheimers Dis. 2022;87(4):1433-1449. doi: 10.3233/JAD-215680.

Neuroinflammation as a Potential Therapeutic Target in Alzheimer's Disease

Liu P, Wang Y, Sun Y, Peng G.

Clin Interv Aging. 2022 Apr 29;17:665-674. doi: 10.2147/CIA.S357558. eCollection 2022.

Potential role of IP3/Ca(2+) signaling and phosphodiesterases: Relevance to neurodegeneration in Alzheimer's disease and possible therapeutic strategies

Jyoti Dutta B, Singh S, Seksaria S, Das Gupta G, Bodakhe SH, Singh A.

Biochem Pharmacol. 2022 Jul;201:115071. doi: 10.1016/j.bcp.2022.115071. Epub 2022 May 4.

Circadian clocks, cognition, and Alzheimer's disease: synaptic mechanisms, signaling effectors, and chronotherapeutics

Hoyt KR, Obrietan K.

Mol Neurodegener. 2022 May 7;17(1):35. doi: 10.1186/s13024-022-00537-9.

Editorial: Aducanumab Trials EMERGE But Don't ENGAGE

Schneider LS.

J Prev Alzheimers Dis. 2022;9(2):193-196. doi: 10.14283/jpad.2022.37.

Lactoferrin as Immune-Enhancement Strategy for SARS-CoV-2 Infection in Alzheimer's Disease Patients

Bartolomé F, Rosa L, Valenti P, Lopera F, Hernández-Gallego J, Cantero JL, Orive G, Carro E.

Front Immunol. 2022 Apr 25;13:878201. doi: 10.3389/fimmu.2022.878201. eCollection 2022.

Trained immunity in viral infections, Alzheimer's disease and multiple sclerosis: A convergence in type I interferon signalling and IFNβ-1a

Vavougios GD, Mavridis T, Artemiadis A, Krogfelt KA, Hadjigeorgiou G.

Biochim Biophys Acta Mol Basis Dis. 2022 Sep 1;1868(9):166430. doi: 10.1016/j.bbadis.2022.166430. Epub 2022 May 10.

Microglia in the Neuroinflammatory Pathogenesis of Alzheimer's Disease and Related Therapeutic Targets

Cai Y, Liu J, Wang B, Sun M, Yang H.

Front Immunol. 2022 Apr 26;13:856376. doi: 10.3389/fimmu.2022.856376. eCollection 2022.

Mechanistic Insights for Drug Repurposing and the Design of Hybrid Drugs for Alzheimer's Disease

Padhi D, Govindaraju T.

J Med Chem. 2022 May 26;65(10):7088-7105. doi: 10.1021/acs.jmedchem.2c00335. Epub 2022 May 13.

Antidiabetic Drugs in the Treatment of Alzheimer's Disease

Michailidis M, Tata DA, Moraitou D, Kavvadas D, Karachrysafi S, Papamitsou T, Vareltzis P, Papaliagkas V.

Int J Mol Sci. 2022 Apr 22;23(9):4641. doi: 10.3390/ijms23094641.

The Role of the Microbiota-Gut-Brain Axis in the Development of Alzheimer's Disease

Wiatrak B, Balon K, Jawień P, Bednarz D, Jęśkowiak I, Szeląg A.

Int J Mol Sci. 2022 Apr 27;23(9):4862. doi: 10.3390/ijms23094862.

A(2A) Adenosine Receptor: A Possible Therapeutic Target for Alzheimer's Disease by Regulating NLRP3 Inflammasome Activity?

Merighi S, Nigro M, Travagli A, Pasquini S, Borea PA, Varani K, Vincenzi F, Gessi S.

Int J Mol Sci. 2022 May 2;23(9):5056. doi: 10.3390/ijms23095056.

A Narrative Review of the Effects of Citrus Peels and Extracts on Human Brain Health and Metabolism

Matsuzaki K, Nakajima A, Guo Y, Ohizumi Y.

Nutrients. 2022 Apr 28;14(9):1847. doi: 10.3390/nu14091847.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias